🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ctDNA

Setting Up ctDNA Analysis on Archived Plasma Samples NCT07546578n/a1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: ctDNA CtDNA Based MRD Testing for NAC Monitoring in TNBC NCT06230185n/a14 sites📍 Tucson📍 Aurora📍 Washington D.C. Personalis Inc. Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab CtDNA-guided Maintenance Therapy in Pancreatic Cancer NCT07054879n/a1 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… ctDNA Assay in Patients With Resectable Pancreatic Cancer NCT05052671n/a2 sites📍 Oklahoma City📍 Tulsa University of Oklahoma ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" NCT07381764Phase 226 sites📍 Alessandria📍 Ancona📍 Aviano Gruppo Oncologico Italia Meridionale · Tests: Erbitux (Cetuximab), Bevacizumab, Irinotecan, Trifluridine/tipiracil Prospective ctDNA Testing in Large B-Cell Lymphoma NCT07878351n/a2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such a… ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites📍 Vienna📍 Baden📍 Dornbirn Austrian Breast & Colorectal Cancer Study Group · Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer NCT05502523NA4 sites📍 Abington📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Pulmonary Artery-First Surgical Technique, Biospecimen Collection Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) NCT04434040Phase 27 sites📍 San Francisco📍 Chicago📍 New Lenox Dana-Farber Cancer Institute · Tests: Atezolizumab, Sacituzumab govitecan Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial NCT06434896NA29 sites📍 's-Hertogenbosch📍 Alkmaar📍 Almelo UMC Utrecht · Tests: ctDNA analysis after surgery Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis NCT07030283Phase 11 site📍 Aurora University of Colorado, Denver · Tests: Paclitaxel, NALIRIFOX A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer NCT06589388n/a1 site📍 Ho Chi Minh City Gene Solutions Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer NCT06706557n/a1 site📍 Milan European Institute of Oncology A Prospective Cohort Study on Colorectal Cancer Screening in Community Population NCT05485077n/a1 site📍 Beijing Singlera Genomics Inc. Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study NCT06105177n/a5 sites📍 Heerlen📍 Maastricht📍 Eindhoven Catharina Ziekenhuis Eindhoven Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System NCT07870265NA1 site📍 Brno Masaryk Memorial Cancer Institute · Tests: Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripher… Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients NCT07673861NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Marsden360 ctDNA test and GTAB review EUS Guided HVA and PVA for Circulating Tumor DNA in Patients NCT04782557NA1 site📍 Hong Kong Chinese University of Hong Kong · Tests: EUS-guided portal vein and hepatic vein aspiration Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218Phase 31 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Docetaxel, Pyrotinib, Trastuzumab (Herceptin), Pertuzumab PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC NCT06977074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: PD-1 inhibitor, Platinum Doublet Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401) NCT06561178n/a1 site📍 Guangzhou Sun Yat-Sen University Cancer Center · Tests: molecular residual disease detection Detection of Minimal Residual Disease Post-prostatectomy NCT07334275n/a1 site📍 Nijmegen Radboud University Medical Center Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer NCT04530890NA1 site📍 Poitiers Poitiers University Hospital · Tests: Blood samples A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Rarecells Molecular Biomarkers for Early Detection of Lung Cancer NCT06546007n/a1 site📍 Roma Rarecells Diagnostics SAS · Tests: CTC-DNA TEMPUS ARIES: A Biobank Registry Platform Study in Oncology NCT06207032n/a32 sites📍 Birmingham📍 Whittier📍 Norwich Tempus AI Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy NCT04616131n/a3 sites📍 DeKalb📍 Geneva📍 Warrenville Northwestern University NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer NCT05572801NA13 sites📍 Herlev📍 Vejle📍 Aarhus Aarhus University Hospital · Tests: AMR B: HPV positive ctDNA guided imaging in follow-up
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy